John A. Vernon

University of North Carolina (UNC) at Chapel Hill

102 Ridge Road

Chapel Hill, NC NC 27514

United States

National Bureau of Economic Research (NBER)

1050 Massachusetts Avenue

Cambridge, MA 02138

United States

SCHOLARLY PAPERS

20

DOWNLOADS
Rank 15,566

SSRN RANKINGS

Top 15,566

in Total Papers Downloads

3,027

CITATIONS
Rank 20,752

SSRN RANKINGS

Top 20,752

in Total Papers Citations

22

Scholarly Papers (20)

European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending

Number of pages: 38 Posted: 27 Sep 2006
Joseph H. Golec and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 786 (29,566)
Citation 1

Abstract:

Loading...

Pharmaceutical, Price Regulation; Profitability; Research and Development

European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending

NBER Working Paper No. w12676
Number of pages: 37 Posted: 20 Nov 2006 Last Revised: 22 Aug 2010
Joseph H. Golec and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 58 (363,005)
Citation 4

Abstract:

Loading...

2.

Pharmaceutical R&D Spending and Threats of Price Regulation

Number of pages: 46 Posted: 18 Mar 2008
Joseph H. Golec, Shantaram P. Hegde and John A. Vernon
University of Connecticut - Department of Finance, University of Connecticut - School of Business and University of North Carolina (UNC) at Chapel Hill
Downloads 284 (105,542)
Citation 7

Abstract:

Loading...

Research and Development, Pharmaceuticals, Price Controls

Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending

Number of pages: 52 Posted: 18 Mar 2005
Joseph H. Golec, Shantaram P. Hegde and John A. Vernon
University of Connecticut - Department of Finance, University of Connecticut - School of Business and University of North Carolina (UNC) at Chapel Hill
Downloads 194 (154,050)
Citation 2

Abstract:

Loading...

Research and Development, Real Options, Price Regulation, Pharmaceutical, Biotechnology

Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending

NBER Working Paper No. w11229
Number of pages: 54 Posted: 20 Nov 2006 Last Revised: 08 Sep 2010
Joseph H. Golec, Shantaram P. Hegde and John A. Vernon
University of Connecticut - Department of Finance, University of Connecticut - School of Business and University of North Carolina (UNC) at Chapel Hill
Downloads 55 (372,740)
Citation 2

Abstract:

Loading...

4.

Exploration of Potential Economics of Follow-On Biologics and Implications for Data Exclusivity Periods for Biologics

Number of pages: 19 Posted: 08 May 2009 Last Revised: 06 Nov 2012
John A. Vernon, A. Bennett and Joseph H. Golec
University of North Carolina (UNC) at Chapel Hill, affiliation not provided to SSRN and University of Connecticut - Department of Finance
Downloads 232 (130,044)

Abstract:

Loading...

5.

Fda New Drug Approval Times, Prescription Drug User Fees, and R&D Spending

AEI-Brookings Joint Center Working Paper No. 06-21
Number of pages: 22 Posted: 20 Sep 2006
University of Connecticut - Department of Finance, University of North Carolina (UNC) at Chapel Hill, American Enterprise Institute (AEI) and U.S. Department of Health & Human Services
Downloads 209 (143,799)
Citation 4

Abstract:

Loading...

FDA, R&D, pharmaceutical

6.

Financial Risk in the Biotechnology Industry

NBER Working Paper No. w13604
Number of pages: 26 Posted: 14 Nov 2007 Last Revised: 25 Nov 2014
Joseph H. Golec and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 176 (168,280)

Abstract:

Loading...

7.

The Cost of Us Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions

NBER Working Paper No. w11114
Number of pages: 36 Posted: 08 Mar 2005
Thomas A. Abbott and John A. Vernon
Thomson-Medstat and University of North Carolina (UNC) at Chapel Hill
Downloads 154 (188,711)
Citation 1

Abstract:

Loading...

8.

Economic Evaluation and Comparative-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation

Number of pages: 22 Posted: 24 Apr 2009
John A. Vernon and Joseph H. Golec
University of North Carolina (UNC) at Chapel Hill and University of Connecticut - Department of Finance
Downloads 141 (202,835)
Citation 2

Abstract:

Loading...

9.

Comparative Effectiveness Research (CER) Policies and the Potential Threat to Pharmaceutical Innovation

Number of pages: 23 Posted: 28 Mar 2010
John A. Vernon, Joseph H. Golec and Stedman Stevens
University of North Carolina (UNC) at Chapel Hill, University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 133 (212,558)

Abstract:

Loading...

Comparative Effectiveness Research, Pharmaceutical Research and Development, Pharmaceutical Regulation, Food and Drug Administration

10.

Data Exclusivity Period Length and Federal Government Savings from Enactment of the Biologics Price Competition and Innovation Act of 2007

Posted: 26 Jan 2009
Ted Buckley, Joseph H. Golec and John A. Vernon
affiliation not provided to SSRN, University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 102 (258,213)

Abstract:

Loading...

R&D, Follow-on Biologics, Data Exclusivity, R&D

11.

The Future of Drug Development: The Economics of Pharmacogenomics

NBER Working Paper No. w11875
Number of pages: 48 Posted: 22 Jan 2006 Last Revised: 20 Sep 2014
John A. Vernon, W. Keener Hughen and John A. Vernon
University of North Carolina (UNC) at Chapel Hill, Sacred Heart University and University of Connecticut - Department of Finance
Downloads 92 (276,190)
Citation 1

Abstract:

Loading...

12.

Assessing Consumer Gains from a Drug Price Control Policy in the U.S

NBER Working Paper No. w11139
Number of pages: 32 Posted: 25 May 2006 Last Revised: 09 Jun 2007
Rexford E. Santerre and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 81 (298,871)
Citation 4

Abstract:

Loading...

13.

Hospital Ownership Mix Efficiency in the Us: An Exploratory Study

NBER Working Paper No. w11192
Number of pages: 26 Posted: 18 Apr 2005 Last Revised: 02 Aug 2010
Rexford E. Santerre and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 68 (330,064)
Citation 2

Abstract:

Loading...

What's the 'Interest' in FDA Drug Advisory Committee Conflicts of Interest?

Number of pages: 25 Posted: 25 Apr 2009
Joseph H. Golec and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 47 (400,391)

Abstract:

Loading...

FDA Advisory Committee Meetings, Conflicts of Interest, Stock Returns, Event Studies

What's the "Interest" in Fda Drug Advisory Committee Conflicts of Interest?

NBER Working Paper No. w14932
Number of pages: 22 Posted: 03 May 2009 Last Revised: 02 Jun 2013
Joseph H. Golec and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 12 (584,275)

Abstract:

Loading...

15.

A Response to the Brill Analysis for Proper Data Exclusivity Periods for Innovator Biologics

Posted: 01 Apr 2009
John A. Vernon and Joseph H. Golec
University of North Carolina (UNC) at Chapel Hill and University of Connecticut - Department of Finance
Downloads 58 (357,817)

Abstract:

Loading...

Follow on Biologics, Data Exclusivity, Biotech Financial Risk

16.

Black Box Warnings and Drug Safety: Examining the Determinants and Timing of Fda Warning Labels

NBER Working Paper No. w12803
Number of pages: 23 Posted: 05 Jan 2007 Last Revised: 02 Jun 2013
U.S. Food and Drug Administration (FDA), U.S. Department of Health and Human Services - Food and Drug Administration (FDA), U.S. Department of Health and Human Services - Food and Drug Administration (FDA), American Enterprise Institute (AEI), U.S. Department of Health & Human Services and University of North Carolina (UNC) at Chapel Hill
Downloads 47 (393,314)
Citation 1

Abstract:

Loading...

17.

Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development Expenditures

NBER Working Paper No. w15723
Number of pages: 23 Posted: 08 Feb 2010 Last Revised: 13 Mar 2013
Joseph P. Cook, Graeme Hunter and John A. Vernon
NERA Economic Consulting, Marsh & McLennan Companies - Securities and University of North Carolina (UNC) at Chapel Hill
Downloads 43 (407,589)

Abstract:

Loading...

18.

Testing for Ownership Mix Efficiency: The Case of the Nursing Home Industry

NBER Working Paper No. w11115
Number of pages: 23 Posted: 08 Mar 2005
Rexford E. Santerre and John A. Vernon
University of Connecticut - Department of Finance and University of North Carolina (UNC) at Chapel Hill
Downloads 33 (447,255)

Abstract:

Loading...

19.

Race and Health Disparities Among Seniors in Urban Areas in Brazil

NBER Working Paper No. w11690
Number of pages: 45 Posted: 16 Dec 2005 Last Revised: 06 Sep 2014
University of Central Florida, University of North Carolina (UNC) at Chapel Hill, University of Connecticut - Department of Finance, CEDEPLAR/UFMG and University of North Carolina at Chapel Hill - College of Health
Downloads 22 (503,160)

Abstract:

Loading...

20.

Determinants of Gender Differences in Health Among Elderly in Latin America

iHEA 2007 6th World Congress: Explorations in Health Economics Paper
Posted: 25 Jun 2007
Antonio J. Trujillo, Thomas A. Mroz and John A. Vernon
University of Central Florida, Department of Economics, Andrew Young School of Policy Studies and University of North Carolina (UNC) at Chapel Hill

Abstract:

Loading...

Elderly, Health, Gender differentials, Caregivers, Latin American